Published December 12, 2023 | Version v1
Journal article Open

Fibroblast Growth Factor-23 importance as a prognostic factor in hemodialysis patients

Creators

  • 1. Consultant Nephrologist, Assistant Professor, College of Medicine, University of Basrah, Iraq
  • 2. Nephrologist and Internist, Baquba teaching Hospital, Iraq. Faten Abdulghani Hammoudi3 Specialist in Laboratory Diagnosis, Baghdad Medical City, Iraq
  • 3. Professor, Consultant Nephrologist and Internist, Baghdad Medical College, Iraq
  • 4. Family Physician, Al Mohandessin Primary Health Care, Basrah, Iraq

Description

Background: Initial complications evident in chronic kidney disease (CKD) are enhanced levels of Fibroblast growth factor 23 (FGF23) and phosphate homeostasis disorders. An increase in FGF23 is a highly sensitive indicator of phosphate toxicity and end-organ toxicity in the heart.

Objective: The objective of the current research was to explore the correlation between the quantity of FGF23 and bone-mineral metabolism, anemia left ventricular hypertrophy (LVH), and dysfunction (LVEF).

Methods: This research was executed at the nephrology units, dialysis department / Baghdad Teaching Hospital, and Basrah Teaching Hospital from 1st of January 2021 to 1 of March 2022. 60 patients undergoing hemodialysis for a minimum of six months were recruited for the research. Parameters assessed included hematocrit (Htc), hemoglobin (Hb), phosphorus (P), calcium (Ca), corrected albumin, and whole parathyroid hormone (iPTH). We further calculated if any correlation existed between these parameters and FGF23 levels. We also conducted left ventricular echocardiography of the recruited patients to evaluate the relation between FGF23, LVH, and LVEF.

Results: We found a statistically significant positive correlation between serum FGF23 levels and iPTH (P < 0.001), and Ca values (P <0.001). However, we were unable to find a substantial correlation between the levels of FGF23 and Hb (P = 0.518) and Htc (P = 0.377). FGF23 and LVH were also statistically correlated (P<0.001). A significant negative correlation of FGF23 was found with LVEF showing a decrease in LVEF with increasing levels of FGF23 (P<0.001).

Conclusion: 

Elevated serum FGF-23 levels in hemodialysis patients showed a significant correlation with various studied parameters indicating its role in the development of hyperparathyroidism. Noticeably, our data showed a positive correlation between FGF23 and LVH and a negative correlation between FGF23 and LVEF suggesting that FGF23 is sufficient to forecast of overall death rate in patients suffering from CKD. 

Files

2 Fibroblast Growth Factor-23.pdf

Files (505.7 kB)

Name Size Download all
md5:05e446c0f88d9d3398152d90f074c1d6
505.7 kB Preview Download

Additional details

References

  • Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management. JAMA [Internet]. 2019 Oct 1;322(13):1294. Available from: https://jamanetwork.com/journals/jama/fullarticle/2752067
  • Ammirati AL. Chronic kidney disease. Revista da Associacao Medica Brasileira. 2020.
  • Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int [Internet]. 2015 Nov;88(5):950–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0085253815609991
  • Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: Global dimension and perspectives. The Lancet. 2013.
  • O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, ttgen AK, Coresh J, et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet. 2011;
  • Tayo BO, Kramer H, Salako BL, Gottesman O, McKenzie CA, Ogunniyi A, et al. Genetic variation in APOL1 and MYH9 genes is associated with chronic kidney disease among Nigerians. Int Urol Nephrol. 2013;
  • Akalin N, Okuturlar Y, Harmankaya Ö, Gedıkbaşi A, Sezıklı S, Koçak Yücel S. Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients. Int J Nephrol [Internet]. 2014;2014:1–6. Available from: http://www.hindawi.com/journals/ijn/2014/602034/
  • White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000
  • Mirza MAI, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis [Internet]. 2009 Dec;207(2):546–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021915009004080
  • Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol [Internet]. 2010;23(6):619–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20658451
  • Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol [Internet]. 2010;23(6):619–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20658451
  • Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest [Internet]. 2004 Feb 15;113(4):561–8. Available from: http://www.jci.org/articles/view/19081
  • Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D. The role of phosphate in kidney disease. Nat Rev Nephrol [Internet]. 2017 Jan 21;13(1):27–38. Available from: http://www.nature.com/articles/nrneph.2016.164
  • Rao DS, Shih M, Mohini R. Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in Uremia. N Engl J Med [Internet]. 1993 Jan 21;328(3):171–5. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199301213280304
  • Rao DS, Shih M, Mohini R. Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in Uremia. N Engl J Med [Internet]. 1993 Jan 21;328(3):171–5. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199301213280304
  • Mirza MAI, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis [Internet]. 2009 Dec;207(2):546–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021915009004080
  • Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Physiol [Internet]. 2010 Oct;299(4):F882–9. Available from: https://www.physiology.org/doi/10.1152/ajprenal.00360.2010
  • Meir T, Durlacher K, Pan Z, Amir G, Richards WG, Silver J, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014;
  • Akalin N, Okuturlar Y, Harmankaya Ö, Gedıkbaşi A, Sezıklı S, Koçak Yücel S. Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients. Int J Nephrol [Internet]. 2014;2014:1–6. Available from: http://www.hindawi.com/journals/ijn/2014/602034/
  • Krajisnik T, Björklund P, Marsell R, Ljunggren O, Åkerström G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol [Internet]. 2007 Oct;195(1):125–31. Available from: https://joe.bioscientifica.com/view/journals/joe/195/1/1940125.xml
  • DeLuca S, Sitara D, Kang K, Marsell R, Jonsson K, Taguchi T, et al. Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23. J Pathol. 2008;
  • Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;
  • Kawakami K, Takeshita A, Furushima K, Miyajima M, Hatamura I, Kuro-O M, et al. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. Sci Rep. 2017;
  • Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, et al. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol [Internet]. 2016 Aug 1;1(5):548. Available from: http://cardiology.jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2016.1445
  • Mirza MAI, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis [Internet]. 2009 Dec;207(2):546–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021915009004080
  • Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;
  • Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;
  • Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. <scp>FGF</scp> 23 regulates renal sodium handling and blood pressure. EMBO Mol Med [Internet]. 2014 Jun 5; 6(6):744–59. Available from: https://onlinelibrary.wiley.com/doi/10.1002/emmm.201303716

This site uses cookies. Find out more on how we use cookies